Developments TG Therapeutics presents new data from Phase 2 and 3 trials of ublituximab TG Therapeutics (NASDAQ:TGTX) presented initial Phase 3 and updated Phase 2 data for ublituximab, an anti-CD20 monoclonal antibody, for the treatment of relapsing forms of multiple sclerosis (RMS). At the 35th Annual... September 13, 2019